<DOC>
	<DOC>NCT01620437</DOC>
	<brief_summary>This trial is conducted in Japan. The aim of this trial is to investigate the bioequivalence of two formulations of biphasic insulin aspart 50 (NN-X14Mix50) in healthy Japanese subjects.</brief_summary>
	<brief_title>Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Japanese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<criteria>BMI (body mass index) between 1929 kg/m^2 (both inclusive) Fasting blood glucose between 3.86.0 mmol/L (both inclusive) Nonsmokers Subjects with a firstdegree relative with diabetes mellitus Subjects smoke 5 cigarettes or more per day</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>